Bupivacaine


Amide local anesthetic (long-acting)

A long-acting butyl-substituted pipecoloxylidide racemic local anesthetic with high cardiotoxicity that motivated development of the (S)-enantiomer levobupivacaine.

Abstract

Bupivacaine (1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide; CAS 2180-92-9; molecular formula C18H28N2O; molecular weight 288.43) is a long-acting amide local anesthetic synthesized by Bo af Ekenstam at AB Bofors in 1957 and introduced clinically in 1965 (Marcaine, Sensorcaine). The compound is the n-butyl analog of mepivacaine and shares the pipecoloxylidide scaffold; the longer alkyl chain confers higher lipid solubility, longer duration, and greater protein binding. Bupivacaine is sold as a racemate of (R)- and (S)-enantiomers; the cardiotoxicity that distinguishes bupivacaine from shorter-acting amides is enantioselectively driven by the (R)-enantiomer, which has higher affinity for cardiac sodium channels and longer dissociation kinetics. Mechanism is voltage-gated sodium channel block, state-dependent and slowly dissociating, the slow kinetics underlying both the prolonged neural block and the elevated arrhythmogenic risk relative to lidocaine. Onset for infiltration is 5 to 10 minutes; duration is 4 to 8 hours, longer with epinephrine adjunct. The principal historical safety concern is cardiac arrest from inadvertent intravascular injection during regional anesthesia: bupivacaine binds the cardiac sodium channel and dissociates slowly, producing ventricular arrhythmias and refractory cardiovascular collapse that proved historically resistant to standard ACLS algorithms. Bupivacaine remains widely used for surgical regional anesthesia (spinal, epidural, peripheral nerve block) and obstetric epidural analgesia.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph